summari ew host annual investor meet decemb
ew re-affirmed guidanc expect regard
underli ww sale guidanc adj ep guidanc
growth ep estim basic in-lin
respect midpoint guidanc see figur
summari key takeaway view includ encourag
tavr guidanc underli came better
expect transcathet mitral tricuspid therapi
tmtt guidanc lower-than-expect
trim tmtt estim impli flat sequenti
growth given sheath issu pascal impact quarter
import pipelin updat unveil
sapien push pascal approv previous
assum overal believ meet reinforc
robust growth opportun ahead compani
beyond encourag tavr guidanc pipelin updat
could view mix invest commun rais
price target assum new ep
estim
rais estim lower tmtt estim
reflect recent pascal guid sheath recal
rais sale estim
underli ep estim
segment sale estim chang stack
follow tavr sale estim
underli surgic heart valv therapi sale rais
underli critic care sale estim
lower underli tmtt
sale estim decreas
continu follow page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
continu previou page
guidanc gener slightli better expect ew expect sale
underli growth basic in-lin midpoint
new estim underli growth prior consensu
underli growth expect ew guid underli growth investor meet
preview therefor today guidanc slightli better expect cadenc perspect
manag continu expect growth first half higher second half due tougher
comp bottom-lin ep guidanc slightli better expect
ew ep guidanc compar new estim bracket
consensu
tavr segment guidanc larg in-lin expect guidanc
transcathet aortic valv replac tavr underli growth versu
current estim underli growth consensu growth
previous assum ew would guid tavr growth outlook better
expect ew also guid transcathet mitral tricuspid tmtt revenu
compar estim consensu ssh surgic structur heart ew
expect sale underli growth compar current model
critic cc ew expect sale underli growth compar
current model
guidanc item ew expect gross margin vs current estim
consensu product mix benefit tavr benefit margin
histor ew expect continu well addit current rate ew anticip
lower fx hedg gain vs ew expect sg vs estim
guidanc assum suspens medic devic tax go back effect would
impact sg manag note conting plan
off-set potenti devic tax impact ew expect sale
vs estim ew expect oper margin vs estim
tax rate expect includ estim etb excess tax benefit
impact compar tax rate estim ew anticip fx headwind
roughli top-lin next year figur summari ew guidanc
long-term global tavr outlook rais investor day ew estim
long-term tavr world-wide market opportun
investor day long term tavr outlook compar model ww per ew
driver growth includ new indic expans increas therapi awar
technolog advanc lastli manag highlight signific opportun go beyond
core market us eu japan long-term plan period rest world row
countri account piec pie rel estim chart
think ew could receiv approv sapien china time-frame
ew guid underli tavr growth manag guid underli tavr
growth sale better expect tavr
guidanc bracket consensu compar current estim underli
basi main driver tavr growth ew perspect includ sapien ultra
continu expans low risk patient key assumpt includ guidanc includ
increas diseas therapi awar new competit result modest share
compress sapien ultra becom major tavr sale eu
modest asp declin result volum discount cadenc perspect manag
note second half grow slower first half given bolu low risk patient result
high growth comp overal believ tavr guidanc robust impli
modestli better-than-expect market growth rel previou think earn call
new sapien valv unveil perhap increment updat product perspect
today meet introduct new tavr valv sapien compani complet success
first-in-man case anticip pivot trial start next month hear much
valv technolog standpoint due competit reason howev learn focu
remain reduc mortal stroke paravalvular leak pvl addit manag mention
durabl discuss would critic would expect ew add resilia valv technolog
sapien compani also highlight enhanc control precis sapien
ew pursu sever asymptomat patient moder symptomat patient
investor day manag provid updat early-tavr evalu use tavr
patient serv asymptomat aortic stenosi ew note patient
patient trial enrol date manag expect fulli enrol trial point
studi featur primari endpoint averag two-year follow lead us believ
could see data point also expect ew eventu initi new moder
transcathet mitral tricuspid therapi tmtt
long-term global tmtt opportun reach ew maintain long-term tmtt
market forecast compar model note model
includ tricuspid tailwind growth period includ address complex unmet need
larg patient popul provid differenti portfolio pipelin technolog develop
clinic devic latter ew current enrol clinic studi pivot trial tmtt
space discuss beyond ew expect replac therapi annular reduct
play larger role market
ew guid tmtt revenu ew introduc guidanc
lower anticip consensu ew previous guid
doubl revenu rel tailwind outlook includ addit evid differenti
patient outcom increas commerci adopt eu center clinic revenu
headwind tmtt outlook includ ip litig risk number random studi
enrol ew would emphas guidanc includ neg
impact ip litig current number assum ew continu oper unencumb
litig lastli manag continu expect bulk tmtt revenu come
pascal
believ flat sequenti revis tmtt estim
previous impli flat sequenti growth remind ew
origin guid sale contribut lower call less
compani note tmtt revenu moder due premium price strategi europ believ
flat sequenti result sheath manufactur issu impact ew
back market current addit midpoint revis tmtt outlook
lower expect color commentari procedur adopt y/i impli doubl
revenu y/i good way think taken togeth believ around
impli expect tmtt revenu
pascal launch expect ew announc first time expect complet
enrol clasp iid trial end clasp iid trial compar pascal abt
mitraclip high-risk degen mitral regurgit mr patient enrol complet timelin
suggest see pivot data expect see data late
anticip approv pascal sometim remov mitral
revenu model current model mitral revenu ew compar
previous
cardioband ew pursu next-gen devic initi random trial
previou concern ew would termin cardioband program given recent challeng
devic howev ew announc plan pursu breakthrough next-gen devic initi
random trial cardioband hear timelin next gener devic would
complet believ take year
sapien pivot remain track evoqu feasibl studi tricuspid
announc transcathet mitral valv replac tmvr front ew remain commit
strategi sapien evoqu fda approv sapien pivot trial compani
plan start trial trial would first-fda approv pivot
transeptal/transfemor approach regard evoqu platform move forward earli
feasibl studi mitral addit compani announc plan initi transcathet tricuspid
feasibl trial evoqu manag state done success human tricuspid
case multipl center thu far
pascal litig bear close monitor although ew briefli touch on-going pascal
litig think investor monitor close timelin includ
uk trial decemb german trial juli us trial may
mention guidanc includ neg impact ip litig
result number assum ew continu oper unencumb litig
updat would increment
ssh growth expect slightli growth expect
ew expect deliv underli revenu growth surgic structur heart busi
slightli mid-point growth expect
outlook slightli better expect flattish growth in-lin
consensu expect reflect continu neg impact tavr convers develop
market europ off-set benefit launch new product well uptak less
penetr tavr region ew commit advanc leadership posit global
surgic market highlight follow driver busi go forward continu strong
global adopt inspiri regulatori approv harpoon echo-guid beating-heart system
europ launch konect resilia system featur first
ready-to-impl tissu valv conduit launch sutrafix autom fasten system
 late manag look drive balanc portfolio less depend
aortic procedur greater focu tap treatment mitral valv diseas
harpoon devic re-launch europ ew complet review harpoon
technolog paus commerci roll-out europ shortli receiv ce mark approv
evalu hand case synthet chord ruptur seen ce mark studi ew found ruptur
result undu tension chord could rectifi proper techniqu train
devic modif requir ew previous expect begin treat patient europ
push timelin confid secur devic approv ye-
ew expect conduct post-market studi part re-launch note harpoon echo-
guid beating-heart procedur standard degen mitral repair procedur manag
believ harpoon signific long-term growth driver address popul stand
 europ japan
inspiri continu notabl growth driver inspiri first surgic valv design
potenti futur valve-in-valv viv procedur featur resilia tissu extend durabl
make product especi attract younger activ patient inspiri continu
receiv strong commerci traction lead valv japan
konect resilia system launch konect system first pre-
assembl ready-to-impl tissu valv conduit help simplifi complex case involv aortic root
well aortic valv replac offer altern surgeon use multipl product
singl off-the-shelf system potenti reduc oper time ew expect launch
europ believ initi annual address popul patient across
sutrafix autom fasten system launch late sutrafix autom
fasten system help streamlin procedur replac manual knot tie autom sutur
fasten manag expect launch late believ product good
uptak valv ring secur autom sutur fasten
critic growth expect outlook ew
expect deliv underli revenu growth critic busi
growth expect outlook bracket expect
growth consensu expect ew three key prioriti critic care
franchis go forward first ew look drive continu uptak hemospher platform aid
technolog integr clearsight assist fluid manag
connect suit full rang technolog integr help creat offer enhanc
recoveri tool strengthen ew leadership smart monitor second ew look
continu shift enhanc surgic recoveri esr smart recoveri acumen sensor
acumen iq technolog predict softwar design prevent low blood pressur event third ew
look expand portfolio integr cerebr oximetri transform technolog
worth note ew estim smart recoveri help expand market opportun
today ew acknowledg long convers cycl slow adopt curv
new technolog potenti headwind busi
price target
price target assum ep estim risk includ greater
share loss model delay mitral program neg clinic data
believ upcom data pipelin product help ew address new competit
transcathet mitral valv opportun signific catalyst
irvin california -base edward lifesci ew develop manufactur market product
design heart valv diseas cardiac surgeri critic care edward revenu reach
billion come transcathet heart valv therapi thv busi ew
player transcathet heart valv therapi market
guidanceexpect guidanceexpect guidanc midpointour estimateconsensu sale sale sale growthexpect sale doublenananasurg structur sale growthflat sale profit interest inc etb inc etb growthfre share tax rate guidanc includ estim etb benefit sourc compani report visibl alpha secur llc estim medic technolog
